Home / Business and Economy / Biotech TRex Bio Nets $116.7M in IPO
Biotech TRex Bio Nets $116.7M in IPO
9 Oct
Summary
- TRex Bio Inc. secured $116.7 million through its US initial public offering.
- The company's IPO shares were priced at $14 each, the bottom of the expected range.
- TRex Bio focuses on developing treatments for autoimmune and inflammatory diseases.
TRex Bio Inc., an early-stage biotechnology company, has garnered $116.7 million from its initial public offering (IPO) in the United States. The company's shares were priced at $14 per share, which fell at the bottom of the marketed price range, indicating a cautious market reception or strategic pricing.
The funds raised are designated to support TRex Bio's ongoing research and development efforts. The company is specifically focused on creating innovative therapies for autoimmune and inflammatory diseases, areas with substantial patient populations and a need for advanced treatment options.
This significant capital infusion positions TRex Bio to advance its pipeline of potential treatments. The company's commitment to tackling complex conditions like autoimmune and inflammatory diseases underscores its ambition to make a meaningful impact on patient health.
